Black­stone bankrolls sup­ply chain play­er's deal spree with $275M

A wheel­ing and deal­ing Black­stone crew isn’t lim­it­ing its fo­cus on drug — or even medtech — R&D. In its lat­est deal, the pri­vate eq­ui­ty firm is splash­ing $275 mil­lion to fund a lo­gis­tics com­pa­ny’s am­bi­tion to seize an even larg­er por­tion of the cell and gene ther­a­py sup­ply chain.

Cry­oport’s ac­qui­si­tion of MVE Bi­o­log­i­cal So­lu­tions, a $320 mil­lion all-cash deal, is its sec­ond buy­out in 4 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER